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a b s t r a c t
Beta-blockers represent a cornerstone of the treatment of symptomatic hypertrophic cardio-
myopathy – they are the ﬁrst-line therapy for obstructive and non-obstructive forms.
Sympathetic modulation leads to the deceleration of heart rate at rest and after exertion,
and unconvincingly to the improvement of left ventricular diastolic function and obstruc-
tion. Medications include also nondihydropyridine calcium channel blockers without signiﬁ-
cant vasodilatory properties, i.e. verapamil and diltiazem. Other medications used are class
IA antiarrhythmic drugs – disopyramide or cibenzoline, which can be administered to patients
with obstructive forms when ﬁrst-line agents have not been effective. Amiodarone and
diuretics can be used in special indications. Some other agents including statins are in
the stage of clinical investigation.
# 2015 The Czech Society of Cardiology. Published by Elsevier Sp. z o.o. All rights
reserved.
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Many publications have been written about medical treatment
of hypertrophic cardiomyopathy (HCM) in past. The ﬁrst one of
them, describing the effect of beta-blockers in HCM [1], was
published shortly after the antihypertensive effect of beta-
blockers had been described for the ﬁrst time. HCM is one of
the few heart disorders, in which the same medications have
been used constantly for several decades. The ﬁrst-line agents
include two main drug groups: beta-blockers and calcium
channel blockers.
Despite the above mentioned facts, pharmacologic treat-
ment of HCM is associated with several ambiguities and
surprising gaps in knowledge, mainly regarding novel agents.
Some drugs tested several decades ago are not already used –
particularly some older beta-blockers [2]. Perhaps, the most
important issue is the fact that vast majority of studies
performed in past had designs incompatible with the present
requirements for drug studies; results of double blinded,
placebo-controlled trials are almost not available in HCM.
If we dealt with pharmacologic treatment of HCM in the
extent the last European classiﬁcation described it [3], this
article would have been quite extensive and complicated.
According to this classiﬁcation, cardiomyopathies are deﬁned
as diseases of the heart, when myocardium is structurally and
functionally abnormal, and other disorders that could cause
the impairment of myocardium as coronary artery disease,
hypertension, heart valve disease, and congenital heart
defects have been excluded. Currently HCM comprises, apart
from idiopathic hypertrophic cardiomyopathy, also other
disorders that are capable of producing myocardial hypertro-
phy as lysosomal storage diseases (Fabry disease), glycogen
storage diseases (Pompe and Danon-type), myocardial hyper-
trophy in Friedreich's ataxia, Noonan syndrome, mitochon-
drial myopathies, and even initial stages of heart amyloidosis
and other disorders. In further text, we will concentrate only
on ‘‘classical’’ idiopathic HCM, which will simplify the topic.
Following review should describe medications used in the
treatment of HCM and summarize our knowledge on the
individual agents and drug groups.
Beta-blockers
Beta-blockers create a cornerstone of the treatment of
symptomatic hypertrophic cardiomyopathy – they are the
ﬁrst-line therapy for obstructive and non-obstructive forms
[2,4]. Beta-blockers were invented by James Black in 1960 as
drugs for treatment of angina pectoris (he was awarded the
Nobel Prize in 1988). Their antihypertensive effect was
described already in 1964, and two years later, a paperdemonstrating good effect of beta-blockers in HCM was
published [1]. The important ﬁndings supporting administra-
tion of beta-blockers in HCM were higher concentrations of
epinephrine in the samples of interventricular septum
acquired during surgery [5] and also increase in left ventricular
gradient associated with exertion and catecholamines [6].
Eight different beta-blockers (propranolol, praktolol, ace-
butol, nethalidol, nadolol, bisoprolol, sotalol, metipranolol)
have been used in patients with HCM in 12 studies comprising
450 individuals [2].
Sympathetic modulation causes the deceleration of heart
rate at rest and after exertion, which could have led to the
improvement of left ventricular diastolic function, but the
evidence supporting this assumption has been found only
in few studies [7,8]. Other studies have not conﬁrmed
improvement of diastolic function with beta-blockers in
patients with HCM [9]. Moreover, positive effect of beta-
adrenergic stimulation on diastolic function was demonstrat-
ed [10], which further questioned the effect of beta-blockers. In
any case, prolongation of diastole improves the coronary
perfusion.
Beta-blockers cause a reduction in maximal contraction
velocity, which can lead to the change in the extent of systolic
anterior movement and so in the magnitude of left ventricular
outﬂow tract obstruction in patients with HCM. However, the
impact on resting gradient is questionable. Intravenous
administration of beta-blockers has more pronounced effect
and can rarely even lead to complete resolution of pressure
gradient [11]. Long-term oral administration of beta-blockers
can inﬂuence the magnitude of obstruction very little, and
some works have not actually showed any change in the
gradient [12].
Beta-blockers can also decrease the rate of supraventricular
and ventricular arrhythmias in patients with HCM [4,8]
although the effect is not convincing [13].
Undoubtedly, beta-blockers can inﬂuence a wide range of
symptoms in HCM patients. Chest pain was diminished or
completely disappeared in 50–70% of patients with HCM
[13,14]. Dyspnea improved only in patients with the most
severe functional limitations – NYHA class III–IV [13].
In HCM, beta-blockers have no impact on prognosis of the
disease or sudden death rate, unlike in coronary artery
disease, although some studies showed some favorable effect
on mortality [14].
Calcium channel blockers
Calcium channel blockers used in HCM include primarily
nondihydropyridine agents without signiﬁcant vasodilatory
properties, i.e. verapamil and diltiazem. The idea to use
calcium channel blockers in HCM was ﬁrst elaborated by
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increased myocardial contractility in HCM that was attributed
to excessive accumulation of intracellular calcium. The
analogy with cardiomyopathies of some experimental ani-
mals, particularly Syrian hamsters, was assumed. In these
animals, high concentrations of calcium were found in
cardiomyocytes, and the development of cardiomyopathy
was prevented by administration of calcium channel blockers.
In humans with HCM, high concentrations of calcium have
also been found, and they could likely be responsible for left
ventricular diastolic dysfunction [16]. There have been
published 12 studies with verapamil (8 ones were prospective)
in 367 patients with HCM and 4 small prospective studies with
diltiazem in 55 patients [2].
Intravenous (or intracoronary) administration of verapamil
led to several favorable effects on diastolic function of the left
ventricle in hearts with obstruction [17–20]. Parameters of
regional and global diastolic function, and left ventricle
obstruction improved. In other works no changes in param-
eters of diastolic function were found after intravenous
administration of verapamil [21]. It also caused decrease in
left ventricular ejection fraction in most cases.
Long-term oral therapy usually has dissimilar and ambiguous
effect. Some works have demonstrated improvement of
diastolic function [22,23], and also improvement of myocardial
ischemia demonstrated by SPECT imaging has been reported
[24]. In experiment, diltiazem prevented development of HCM
in mice [25,26]. There is a study under way testing hypothesis
that similar effect could prevent development of human HCM
in individuals with positive genotype but still normal
phenotype.
The left ventricle can slightly enlarge during long-term use
of verapamil [19,27] even though other authors have not found
these changes [28,29]. Kaltenbach et al. demonstrated regres-
sion of left ventricular hypertrophy with verapamil [28], but
our group did not prove a similar effect [30].
Calcium channel blockers usually inﬂuence positively
symptoms and exercise capacity. In our study, NYHA class
improved by at least 1 grade in 57% of patients using calcium
channel blockers [30]. Number of patients who improved was
however lower than the one reported by Kaltenbach (75%) [28],
Rosing (80%) [29], or even Troesch (100%) [31]. In our study,
syncope rate was also lower in treated patients [30].
The initial dose of verapamil is usually 40 mg orally 3
times a day with upward titration to a maximum dose of
480 mg a day, and the starting dose of diltiazem is 60 mg 3
times a day with a maximum dose 360 mg a day. Generally,
calcium channel blockers are usually used if beta-blockers
are not effective [32]. In children, beta-blockers are more
usual therapy than calcium channel blockers because there
is less evidence available for verapamil use in children.
However, basically, verapamil treatment is possible in
children [32]. Verapamil use in patients with severe obstruc-
tion (≥100 mm Hg) requires careful follow-up since it can
rarely lead to further worsening (often critical) of left
ventricular obstruction.
Majority of clinical experience does not support combina-
tion therapy of verapamil and beta-blockers and this combi-
nation is considered contraindicated in most patients. The
combination did not bring any favorable effect in HCM eitheralthough some works suggested some positive effect in
patients with HCM and recurrent ventricular tachycardia [33].
Class IA antiarrhythmics
If ﬁrst-line therapy (beta-blockers and calcium channel
blockers) is not effective, class IA antiarrhythmics may be
used in patients with HCM.
Disopyramide
Disopyramide was ﬁrst tested in HCM by Canadian authors
[34], and they demonstrated decrease of left ventricular
obstruction with this treatment. Disopyramide is usually used
in combination with beta-blockers. They are often adminis-
tered as a bridge to planned myectomy or alcohol septal
ablation [35]. The target dose is 400–600 mg a day. Adverse
effects include prolongation of QT interval (disopyramide
should not be used concurrently with other drugs prolonging
QT interval, e.g. amiodarone), which has aroused concerns
about proarrhythmogenic effects of the drug. Anticholinergic
adverse effects are also not rare (dry mouth and eyes,
obstipation, and urine retention). This antiarrhythmic is not
used in the Czech Republic.
Cibenzoline
The use of cibenzoline in obstructive forms was ﬁrst suggested
by Japanese authors [9,36]. In contrast to disopyramide,
anticholinergic effect is only small. Cibenzoline probably
improves also some parameters of left ventricular diastolic
function, and so according to authors, it could be eligible for
treatment of non-obstructive forms of HCM [36]. The drug is
not available in the Czech Republic.
Amiodarone
Amiodarone is undoubtedly an effective drug, which, however,
was from the beginning associated with inadequate hope in
HCM. Amiodarone administration was recommended in all
patients with HCM with the goal to improve disease prognosis
by suppression of life-threatening malignant ventricular
arrhythmias [37]. This expectation however was not fulﬁlled,
and even some adverse effects of amiodarone were reported
[38]. This drug is very effective in the treatment of atrial
ﬁbrillation, but no works studying its effect in patients with
HCM has been published [2]. Amiodarone is often used in
patients with an implantable cardioverter-deﬁbrillator to
lower the number of discharges for ventricular arrhythmias.
It is usually administered together with beta-blockers in this
indication [2,32].
Diuretics
Diuretics can be used in HCM patients with serious dyspnea
and pulmonary congestion. Nevertheless, it is important to
prevent dehydration that can aggravate the situation in HCM.
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ACE inhibitors
The results of studies with ACE inhibitors in HCM are not
convincing [39,40]. These drugs cannot be used in obstructive
forms.
Angiotensin receptor blockers
The effect of candesartan seems promising in HCM without left
ventricular obstruction. Our works showed possible favorable
effect of candesartan in terms of myocardial hypertrophy [41–
44]. The newest study of Axelsson and coworkers showed no
signiﬁcant effect of losartan to left ventricular mass [45],
further studies need, however, to be performed for ﬁnal
conclusions.
Valsartan can decrease type I collagen synthesis in HCM and
so probably affect myocardial ﬁbrosis [46], but certainly, there
is a long way to go to better understand this effect and the
impact on the disease as whole.
Other drugs
Atorvastatin can positively inﬂuence myocardial hypertrophy
in HCM, and similar effect was demonstrated in experiment
for simvastatin [47]. Atorvastatin can prevent development of
HCM in experimental animals [48] – the data of this pilot study
need further conﬁrmation. In experimental studies, N-acet-
ylcysteine [8] and trimetazidine [49] were also tested in animal
models.
To completely cover the topic of medical treatment of HCM
also other information on pharmacotherapy in speciﬁc
situations such as left ventricular systolic dysfunction, alcohol
septal ablation with concentrated alcohol, and others should
have been included. This information is however beyond the
scope of this paper and is available in other documents [50,51].
HCM with left ventricular obstruction is also associated with
moderate risk of infective endocarditis, and antimicrobial
prophylaxis is reasonable.
In common clinical practice, we often face a question
whether to treat asymptomatic patients with HCM (e.g. should
we start medication in patients with signiﬁcant obstruction?).
There is no evidence available that would justify or deny
prophylactic or empiric treatment with beta-blockers, calcium
channel blockers, or other drugs. The decision is usually left
to an experienced physician and is made on individual basis.
Young, asymptomatic patients with HCM or mutation carriers
have quite low risk of complications, thus in majority of them,
we will not start medical treatment.
Which medication should be rather avoided in HCM?
Certainly, we should be careful with higher doses of diuretics
or drugs with vasodilatory properties, which are used
particularly for treatment of hypertension. These drugs can
lead to worsening of obstruction [4]. Digoxin and other drugs
with inotropic effect can also negatively affect magnitude of
obstruction.Conﬂict of interest
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